Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials

Anne M Wallace, Linda K Han, Stephen P Povoski, Kenneth Deck, Schlomo Schneebaum, Nathan C Hall, Carl K Hoh, Karl K Limmer, Helen Krontiras, Thomas G Frazier, Charles Cox, Eli Avisar, Mark Faries, Dennis W King, Lori Christman, David R Vera, Anne M Wallace, Linda K Han, Stephen P Povoski, Kenneth Deck, Schlomo Schneebaum, Nathan C Hall, Carl K Hoh, Karl K Limmer, Helen Krontiras, Thomas G Frazier, Charles Cox, Eli Avisar, Mark Faries, Dennis W King, Lori Christman, David R Vera

Abstract

Background: Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.

Methods: A total of 13 centers contributed 148 patients with breast cancer. Each patient received [(99m)Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [(99m)Tc]tilmanocept.

Results: A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [(99m)Tc]tilmanocept for a concordance rate of 99.04 % (p < 0.0001). [(99m)Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [(99m)Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131, p < 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [(99m)Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (p = 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [(99m)Tc]tilmanocept.

Conclusion: [(99m)Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [(99m)Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.

Figures

Fig. 1
Fig. 1
[99mTc]Tilmanocept is composed of a dextran backbone (black) to which are attached multiple units of mannose (green) and DTPA (blue). The mannose units provide a molecular mechanism by which [99mTc]tilmanocept avidly binds to a receptor specific to recticuloendothelial cells (CD206), and the DTPA units provide a highly stable means to radiolabel tilmanocept with technetium-99m (red). The molecular weight of [99mTc]tilmanocept is approximately 17,000 grams per mole; the molecular diameter is 7.1 nm
Fig. 2
Fig. 2
Lymphoscintigraphy of a 35-year-old woman with carcinoma in situ of the left breast showing 2 intense foci of noted [99mTc]tilmanocept localization within the left axilla. An intradermal injection (0.4 mL, 0.5 mCi, 3.0 nmol) of [99mTc]tilmanocept was administered to the upper left quadrant of the left breast. The SPECT/CT image is a fused sagittal cross section acquired 1 h postinjection, which visualizes a sentinel lymph node (arrow) and the injection site. At 5 h after injection, 3 blue and hot lymph nodes (6,724 cps, 1,477 cps, 167 cps) were detected at surgery and excised. Pathologic examination revealed 1 histologically positive lymph node (blue with 6,700 cps, 1.7 × 1.3 × 0.7 cm) and 2 negative lymph nodes

References

    1. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575. doi: 10.1001/jama.2011.90.
    1. Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol. 2004;85:102–111. doi: 10.1002/jso.20022.
    1. Krag DN. Current status of axillary lymph node dissection and sentinel node biopsy in breast cancer. Clin Adv Hematol Oncol. 2010;8:471–473.
    1. Rodier J, Janser J. Surgical technical details improving sentinel node identification in breast cancer. Oncol Rep. 1997;4:281–283.
    1. Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg. 2004;199:804–816. doi: 10.1016/j.jamcollsurg.2004.05.277.
    1. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–278. doi: 10.1097/00000658-199709000-00006.
    1. Martin RC, 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128:139–144. doi: 10.1067/msy.2000.108064.
    1. Cody HS, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13–19. doi: 10.1007/s10434-001-0013-9.
    1. Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: [99mTc]DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951–959.
    1. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med. 1990;172:1785–1794. doi: 10.1084/jem.172.6.1785.
    1. Wallace AM, Hoh CK, Vera DR, Darrah D, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531–538. doi: 10.1245/ASO.2003.07.012.
    1. Leong SPL, Kim J, Ross MI, Faries M, Scoggins CR, Metz WL, et al. A phase 2 study of [99mTc]tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961–969. doi: 10.1245/s10434-010-1524-z.
    1. Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913–921. doi: 10.1245/s10434-006-9099-4.
    1. Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849–853. doi: 10.1016/j.nucmedbio.2007.05.003.
    1. Wallace AM, Hoh CK, Limmer KK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a “2-day” protocol. Nucl Med Biol. 2009;36:687–692. doi: 10.1016/j.nucmedbio.2009.04.007.
    1. Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, et al. Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680–688. doi: 10.1245/s10434-012-2612-z.
    1. Faries MB, Morton DL. Surgery and sentinel lymph node biopsy. Semin Oncol. 2007;34:498–508. doi: 10.1053/j.seminoncol.2007.09.010.
    1. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–888. doi: 10.1016/S1470-2045(07)70278-4.
    1. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–432.
    1. Rayhanabad J, Yegiyants S, Putchakayala K, Haig P, Romero L, Difronzo LA. Axillary recurrence is low in patients with breast cancer who do not undergo completion axillary lymph node dissection for micrometastases in sentinel lymph nodes. Am Surg. 2010;76:1088–1091.
    1. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–421. doi: 10.1056/NEJMoa1008108.
    1. Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol. 1999;6:12–14. doi: 10.1007/s10434-999-0012-9.
    1. Meyer-Rochow GY, Martin RC, Harman CR. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J Surg. 2003;73:815–818. doi: 10.1046/j.1445-2197.2003.02783.x.
    1. Cope FO, Metz WL, Potter B, Abbruzzese B, Blue M, Shuping J, et al. The novel receptor targeted (CD206) 99mTc-labeled tilmanocept versus the currently employed 99mTc-sulfur colloid in intraoperative lymphatic mapping (ILM) on key performance metrics in breast cancer. J Clin Oncol. 2012;30(15 suppl):e21066.
    1. Tokin CA, Cope FO, Metz WL, Blue MS, Potter BM, Abbruzzese BC, et al. The efficacy of tilmanocept in sentinel lymph node mapping and identification in breast cancer patients: A comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis. 2012;29:681–686. doi: 10.1007/s10585-012-9497-x.
    1. Vera DR, Hoh CK, Hall DJ, Tokin CA, Wallace AM. [99mTc]Tilmanocept: A synthetic receptor-targeted molecule for sentinel lymph node mapping. Radiopharmaceuticals for Sentinel Lymph Node Detection. Vienna: International Atomic Energy Agency (in press).
    1. Ege GN. Internal mammary lymphoscintigraphy—the rationale, technique, interpretation and clinical application: a review based on 848 cases. Radiology. 1976;118:101–107.
    1. Larson SM, Nelp WB. Radiopharmacology of a simplified technetium-99m-colloid preparation for photoscanning. J Nucl Med. 1966;7:817–826.
    1. Ting R, Aguilera TA, Crisp JL, Hall DJ, Eckelman WC, Vera DR, et al. Fast 18F labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes. Bioconjug Chem. 2010;21:1811–1819. doi: 10.1021/bc1001328.
    1. Emerson DK, Limmer KK, Hall DJ, Han SH, Eckelman WC, Kane CJ, et al. A receptor-targeted fluorescent radiopharmaceutical for multi-reporter sentinel lymph node imaging. Radiology. 2012;265:186–193. doi: 10.1148/radiol.12120638.
    1. van der Poel HG, Buckle T, Brouwer OR, Olmos RAV, van Leeuwen FWB. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodel tracer. Eur Urol. 2011;60:826–833. doi: 10.1016/j.eururo.2011.03.024.
    1. Kawaguchi Y, Ishizawa T, Masuda K, Sato S, Kaneko J, Aoki T, et al. Hepatobiliary surgery guided by a novel fluorescent imaging technique for visualizing hepatic arteries, bile ducts, and liver cancers on color images. J Am Coll Surg. 2011;212:e33–e39. doi: 10.1016/j.jamcollsurg.2011.03.006.
    1. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. Acad Radiol. 2004;11:1361–1369. doi: 10.1016/j.acra.2004.11.016.
    1. Stroup SP, Kane CJ, Farchshchi-Heydari S, James CM, Davis CH, Wallace AM, et al. Preoperative sentinel lymph node mapping of the prostate using PET/CT fusion imaging and Ga-68-labeled tilmanocept in a dog model. Clin Exp Metastasis. 2012;29:673–680. doi: 10.1007/s10585-012-9498-9.
    1. Summary of product characteristics for nanocoll, kit for radiopharmaceutical preparation. Milan: GE HEALTHCARE S.R.L.; 2009.
    1. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3. Philadelphia: Saunders; 2003.
    1. Krag DN, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339:941–946. doi: 10.1056/NEJM199810013391401.
    1. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933. doi: 10.1016/S1470-2045(10)70207-2.
    1. McMasters KM, Tuttle T, Carlson D, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–2566.
    1. Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, et al. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg. 2008;207:853–858. doi: 10.1016/j.jamcollsurg.2008.08.008.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться